Effects of vitamin D status and supplementation on MASLD severity in individuals with overweight or obesity: a cross-sectional study and randomized controlled trial.

Plain-language guide to PMID 42474689 (2026): randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 505 adults.

Key Facts

PMID: 42474689
Journal: Journal of endocrinological investigation
Year: 2026
Study type: Randomized Controlled Trial
Authors: Yu L et al. (7 authors)
DOI: 10.1007/s40618-026-02988-z

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The researchers examined the association between serum 25-hydroxyvitamin D [25(OH)D] and non-invasive parameters of MASLD severity and evaluated whether vitamin D3 supplementation, as an adjunct to lifestyle modification, influenced these parameters in adults with overweight or obesity and MASLD.

Why It Was Studied

The study was registered with the Chinese Clinical Trial Registry (ChiCTR2100044305) on 16 March 2021. https://www.chictr.org.cn/showproj.html?proj=123441.

Who Took Part

The abstract describes 505 adults taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A cross-sectional analysis of 505 adults with overweight or obesity and MASLD assessed associations between serum 25(OH)D and non-invasive liver parameters.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

What Was Measured

PubMed files the paper under topics including Cross-Sectional Studies, Obesity, Dietary Supplements, Overweight, Vitamin D, Non-alcoholic Fatty Liver Disease and Vitamin D Deficiency.

Author keywords: 25-hydroxyvitamin D, Metabolic dysfunction-associated steatotic liver disease and Non-invasive parameters.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 505 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.